ImmunityBio, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IBRX in the last 30 days.
See all $IBRX insider activity →ImmunityBio (IBRX) shares rose 9.94% to $9.29 after its founder met with Turkish President Erdogan, sparking expansion hopes. The company's Anktiva drug, approved in 34 countries, drove Q2 revenue to $51.24M, up 94% YoY, though net loss widened to $230.39M. Hedge fund holdings increased 62.6% QoQ to $314.9M.
ImmunityBio (IBRX) shares rose after founder Patrick Soon-Shiong hinted at tokenizing stocks via Nant's blockchain platform. Soon-Shiong, who owns 65.5% of IBRX, cited the SEC's new framework for tokenized securities. Retail traders speculated about potential tokenization of IBRX and PDS Biotechnology (PDSB), with IBRX up 328% year-to-date.
Johnson & Johnson and Pfizer are targeting early-stage cancer assets, focusing on Sellas Life Sciences (SLS), ImmunityBio (IBRX), and Iovance Biotherapeutics (IOVA). SLS's SLS009 showed 46%-50% response rates in AML, while Iovance expects lung-cancer data in Q4. J&J's CEO highlighted M&A interest in early-stage opportunities, with recent deals like Halda Therapeutics and Firefly Bio. IOVA, IBRX, and SLS stocks rose 8%, 6%, and 2% respectively on Monday.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning IBRX (ImmunityBio, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent IBRX coverage spans corporate actions, financial news and market movers.
The fresh $100 M financing and high‑profile meeting suggest near‑term upside, supporting the price surge.
Speculative announcement may boost short‑term sentiment but no concrete transaction disclosed.
Short‑term rally on acquisition speculation.
The financing provides near‑term capital for debt repayment and development, likely supporting IBRX's pipeline and short‑term price momentum.
Similar to SLS, the news is supportive sentiment ahead of clinical milestones.
AlphAI scores every news story that mentions IBRX with an AI model for sentiment and relevance, and aggregates insider trades from ImmunityBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ImmunityBio (IBRX) shares rose 9.94% to $9.29 after its founder met with Turkish President Erdogan, sparking expansion hopes. The company's Anktiva drug, approved in 34 countries, drove Q2 revenue to $51.24M, up 94% YoY, though net loss widened to $230.39M. Hedge fund holdings increased 62.6% QoQ to $314.9M.
2 min readImmunityBio (IBRX) shares rose after founder Patrick Soon-Shiong hinted at tokenizing stocks via Nant's blockchain platform. Soon-Shiong, who owns 65.5% of IBRX, cited the SEC's new framework for tokenized securities. Retail traders speculated about potential tokenization of IBRX and PDS Biotechnology (PDSB), with IBRX up 328% year-to-date.
2 min readJohnson & Johnson and Pfizer are targeting early-stage cancer assets, focusing on Sellas Life Sciences (SLS), ImmunityBio (IBRX), and Iovance Biotherapeutics (IOVA). SLS's SLS009 showed 46%-50% response rates in AML, while Iovance expects lung-cancer data in Q4. J&J's CEO highlighted M&A interest in early-stage opportunities, with recent deals like Halda Therapeutics and Firefly Bio. IOVA, IBRX, and SLS stocks rose 8%, 6%, and 2% respectively on Monday.
2 min readImmunityBio (IBRX) shares rose 6% after Nant Capital, led by IBRX founder Soon-Shiong, invested $11.3M in PDS Biotech (PDSB), with an option to license PDS0101. PDSB shares surged 35%. The deal ties Soon-Shiong to another immunotherapy platform, extending his cytokine and cancer-vaccine strategy. Proceeds will support PDSB's debt repayment and late-stage development.
2 min readU.S. stock futures rose early Thursday, with Dow up 0.4% and S&P 500 up 0.2%, ahead of PPI data and jobless claims. NVDA faced SEC filings and DOJ scrutiny, AAPL launched new iPhones, META acquired Stilla.ai, TSM reported 53.3% sales jump, and TSLA faced EV market concerns. Key earnings: ORCL, ADBE.
7 min readManulife increased its stakes in Sellas Life Sciences (SLS) and ImmunityBio (IBRX) by 7.1% and 27.5% respectively in Q2. SLS is nearing final analysis of its Phase 3 Regal trial, while IBRX awaits an FDA decision on Anktiva's label expansion by Jan. 6, 2027. Both stocks declined on Wednesday.
2 min readU.S. stock futures fell early Monday due to tariff uncertainty and Iran tensions. Nasdaq, S&P 500, and Dow futures declined 0.5%-0.6%. Nvidia's earnings, Netflix's board controversy, and Honeywell's acquisition are in focus. Precious metals rose, with gold above $5,100 and silver near $88/oz.
2 min readImmunityBio (IBRX) shares rose 6% premarket after Saudi FDA encouraged regulatory filing for its rBCG treatment. The company plans to submit the filing soon and is discussing broader use of ANKTIVA for multiple cancers. ANKTIVA is already approved in Saudi Arabia for bladder and lung cancer. The stock has gained over 210% this year.
1 min readImmunityBio (IBRX) shares are up 9% this week, despite a Q1 net loss of $632.8M and a 7% drop post-earnings. The company's founder highlighted a decade-old study showing safety and efficacy of NK-92 cells, and plans for a new Anktiva combination trial. Anktiva saw 168% revenue growth and is now available in Saudi Arabia. The FDA is reviewing Anktiva's supplemental application, with a decision expected soon.
3 min readImmunityBio (IBRX) founder Patrick Soon-Shiong supported Trump's psychedelic research push and shared new data linking low immune-cell levels to higher breast cancer recurrence risk, highlighting Anktiva. IBRX stock rose 6% last week. Soon-Shiong cited studies showing lymphopenia increases recurrence risk and discussed Anktiva's potential in treating immune dysfunction. The company faces FDA scrutiny over promotional claims but is expanding Anktiva's trials and global approvals.
2 min read
